EXAI Exscientia
- 4.950
- +0.270+5.77%
Exscientia News
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday.Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Ba
Form 144 | Exscientia(EXAI.US) Officer Proposes to Sell 131.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 24, $Exscientia(EXAI.US)$ Officer Hallett David intends to sell 30,000 shares of its common stock on Apr 24, with a total market value of approximately $131.4K. Hallett D
Moderna and OpenAI in Pact to Fast-track Drug Development
Exscientia Plc Calls for 2024 Shareholder Votes
Exscientia Is Maintained at Equal-Weight by Morgan Stanley
Exscientia Is Maintained at Equal-Weight by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Exscientia, Maintains $7 Price Target
Morgan Stanley analyst Vikram Purohit maintains Exscientia with a Equal-Weight and maintains $7 price target.
Exscientia Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 65.09% Morgan Stanley $7 → $7 Maintains Equal-Weight 01/05/2024 112.26% B of A Securities $11 →
Form 144 | Exscientia(EXAI.US) Officer Proposes to Sell 188.33K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 8, $Exscientia(EXAI.US)$ Officer Krams Michael intends to sell 39,400 shares of its common stock on Apr 8, with a total market value of approximately $188.33K. Source: A
Analysts' Top Healthcare Picks: Healthequity (HQY), Exscientia Plc (EXAI)
Exscientia GAAP EPS of -$0.42 Beats by $0.91, Revenue of $3.1M Misses by $43.5M
Earnings Call Summary | Exscientia(EXAI.US) Q4 2023 Earnings Conference
The following is a summary of the Exscientia Plc (EXAI) Q4 2023 Earnings Call Transcript:Financial Performance:Exscientia concluded the year with a bank balance of $463 million in cash and fixed-term
Exscientia Shares Drop on 4Q Loss, Revenue Miss
By Sabela Ojea Shares of Exscientia on Thursday dropped after the company reported a wider-than-expected loss and a significant drop in revenue for the fourth quarter. At 2:31 p.m. ET, shares were d
32 "Breakthroughs" Stocks by BofA - Part 2
Exscientia Plc Files For Mixed Shelf Of Up To $300M
Exscientia Plc Files For Mixed Shelf Of Up To $300M
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
Exscientia Plc Reports Progressive Drug Pipeline
BILI, EXAI and ENVB Among Pre-market Losers
Exscientia's 2023 Cash, Cash Equivalents And Short Term Bank Deposits As Of December 31, 2023 Were $462.6M Expected To Provide Cash Runway Into 2026
Exscientia's 2023 Cash, Cash Equivalents And Short Term Bank Deposits As Of December 31, 2023 Were $462.6M Expected To Provide Cash Runway Into 2026
Exscientia Q4 GAAP EPS $(0.42) Misses $(0.35) Estimate, Sales $3.10M May Not Be Comparable To $17.05M Estimate
Exscientia Q4 GAAP EPS $(0.42) Misses $(0.35) Estimate, Sales $3.10M May Not Be Comparable To $17.05M Estimate
Exscientia 4Q Loss/Shr 42c >EXAI
Exscientia 4Q Loss/Shr 42c >EXAI
Analysis
Price Target
No Data
